Clinical Update - Debio 025 in H...(maceuticalpartners for sales and marketi...),Health

Date:4/28/2009

maceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

    Debiopharm S.A. Contact:
    Maurice Wagner,
    Director Corporate Affairs & Communications,
    Tel.: +41(0)21-321-01-11,
    Fax: +41(0)21-321-01-69,
    mwagner@debiopharm.com.

    Additional Media Contacts:

    In London,
    Maitland,
    Brian Hudspith,
    Tel: +44(0)20-7379-5151,
    bhudspith@maitland.co.uk.

    In New York,
    Russo Partners, LLC,
    Martina Schwarzkopf, Ph.D.,
    Account Executive,
    Tel: +1-212-845-4292,
    Fax: +1-212-845-4260,
    martina.schwarzkopf@russopartnersllc.com.

'/>"/>

SOURCE Debiopharm Group Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
7. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
8. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
11. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study